scispace - formally typeset
N

Navjotsingh Pabla

Researcher at Ohio State University

Publications -  44
Citations -  3621

Navjotsingh Pabla is an academic researcher from Ohio State University. The author has contributed to research in topics: Cisplatin & Acute kidney injury. The author has an hindex of 21, co-authored 33 publications receiving 3052 citations. Previous affiliations of Navjotsingh Pabla include Charlie Norwood VA Medical Center & Georgia Regents University.

Papers
More filters
Journal ArticleDOI

A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury.

TL;DR: It is proposed that Cdkl5 is a stress-responsive kinase that promotes renal injury in part through phosphorylation-dependent suppression of pro-survival transcription regulator Sox9, and kinome-wide screening approaches reveal a pathogenic role of CDKL5 kinase in acute kidney injury, which is dependent on suppression of a SOX9-associated transcriptional network.
Journal ArticleDOI

Role of Passive Diffusion, Transporters, and Membrane Trafficking-Mediated Processes in Cellular Drug Transport.

TL;DR: It is proposed that better experimental models are required to elucidate the differential contributions of various processes in intracellular drug accumulation and the role of membrane‐trafficking in drug transport remains underappreciated and unexplored.
Journal ArticleDOI

Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization.

TL;DR: It is reported that the VHL protein (pVHL) may be a substrate of Nek1, and non-phosphorylable pVHL reconstituted in VHL-deficient cells induces more stable cilia than wild-type VHL during serum stimulation and Nocodazole treatment.
Journal ArticleDOI

Nek1 interacts with Ku80 to assist chromatin loading of replication factors and S-phase progression

TL;DR: It is reported that loss of Nek1 results in severe proliferation defect due to a delay in S-phase of the cell cycle, and Nek1 may facilitate S- phase progression by interacting with Ku80 and regulating chromatin loading of replication factors.
Journal ArticleDOI

Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.

TL;DR: The role of Rb1 is delineated in AKI and the pharmacological basis of the renal protective effects of ribociclib during cisplatin nephrotoxicity is illustrated, which is likely dependent on the maintenance of R b1 in a hypo-phosphorylated and functionally active form under stress conditions.